Search Results for: prostate cancer

Rosetta Genomics, Ltd has announced the commercial availability of its second diagnostic test, miRview mets. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

Aureon Laboratories Inc, has announced it has been granted patents to cover the company’s systems and methods for evaluating the occurrence of any medical condition in a patient where clinical, imaging and molecular data are combined and appraised.

CombiMatrix Corporation has announced the introduction of the ProScan, which complements the company’s growing portfolio of array-based diagnostic tests.

Common painkillers like aspirin and ibuprofen appear to lower a mans PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer.